Tumor radiosensitizers - Current status of development of various approaches: Report of an International Atomic Energy Agency meeting

International Journal of Radiation Oncology Biology Physics

Volumn 64, Issue 2, 2006, Pages 551-561

  Horsman, Michael R ^a   Bohm, Lothar ^b   Margison, Geoffrey P ^c   Milas, Luka ^d   Rosier, Jean Francois ^e   Safrany, Geza ^f   Selzer, Edgar ^g   Verheij, Marcel ^h   Hendry, Jolyon H ⁱ  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e CH Joliment Lobbes   (Belgium)

^f National Research Institute for Radiobiology and Radiohygiene Budapest   (Hungary)

^g UNIVERSITY OF VIENNA   (Austria)

^h ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

ⁱ INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

Author keywords

IAEA; Meeting report; Radiosensitizers; Tumors

Indexed keywords

CELL SIGNALING PATHWAYS; IAEA; MEETING REPORT; RADIOSENSITIZERS;

ANTIBODIES; DISEASE CONTROL; DRUG PRODUCTS; ONCOLOGY; TOXICITY; TUMORS;

RADIOTHERAPY;

1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; CARBOGEN; CELECOXIB; CETUXIMAB; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; CYCLOOXYGENASE 2; CYTOTOXIN; DORANIDAZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLOXURIDINE PHOSPHATE; FLUOROURACIL; GANCICLOVIR; GEFITINIB; GEMCITABINE; MISONIDAZOLE; MITOMYCIN C; NICOTINAMIDE; NIMORAZOLE; NITROIMIDAZOLE; OBLIMERSEN; PENTOXIFYLLINE; PERIFOSINE; PHOSPHORYLCHOLINE; RADIOSENSITIZING AGENT; RITUXIMAB; TIRAPAZAMINE; UNCLASSIFIED DRUG;

APOPTOSIS; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; GENE THERAPY; HUMAN; HYPOXIA; MEDICAL PRACTICE; META ANALYSIS; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; SIDE EFFECT; SYSTEMATIC REVIEW; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CELL HYPOXIA; CYCLOOXYGENASE 2 INHIBITORS; GENE THERAPY; INTERNATIONAL AGENCIES; NEOPLASMS; OLIGORIBONUCLEOTIDES, ANTISENSE; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 30544450340     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.09.032     Document Type: Conference Paper

References (102)

1. T.S. Lawrence, A.W. Blackstock, C. McGinn The mechanism of action of radiosensitization of conventional chemotherapeutic agents Semin Radiat Oncol 13 2003 13 21
2. V. Gregoire, W.N. Hittelman, J.F. Rosier Chemo-radiotherapy Radiosensitizing nucleoside analogues Oncol Reps 6 1999 949 957
3. J.F. Rosier, M. Beauduin, M. Bruniaux The effect of 2′-2′ difluoro-deoxycytidine on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity Int J Radiat Biol 75 1999 245 251
4. F.M. Wachters, J.W.G. van Putten, J.G. Maring Selective targeting of homologous DNA recombination repair by gemcitabine Int J Radiat Oncol Biol Phys 57 2003 553 562
5. J.F. Rosier, L. Michaux, G. Ameye The radioenhancement of two human head and neck squamous carcinoma cell lines by 2′-2′ difluoro- deoxycytidine is mediated by an increase in radiation-induced residual chromosome aberrations but not residual DNA DSBs Mut Res Fund Mol Mech Mutag 527 2003 15 26
6. J.F. Rosier, M. Bruniaux, B. Husson Role of 2′-2′ difluoro-deoxycytidine (gemcitabine)-induced cell cycle dysregulation in radio-enhancement of human head and neck squamous cell carcinomas Radiother Oncol 70 2004 55 61
7. T.S. Lawrence, A. Eisbruch, C.J. McGinn Radiosensitization by gemcitabine Oncology 13 1999 55 60
8. M.A. Joschko, L.K. Webster, J. Grover Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumour xenograft model Radiat Oncol Invest 5 1997 62 71
9. M.T. Fields, A. Eisbrush, D. Normolle Radiosensitization produced in vivo by once vs. twice-weekly 2′-2′ difluoro-deoxycytidine (gemcitabine) Int J Radiat Oncol Biol Phys 47 2000 785 791
10. C.H. Crane, R.A. Wolf, J.L. Abbruzzese Combining gemcitabine with radiation in pancreatic cancer Understanding important variables influencing the therapeutic index Semin Oncol 28 Suppl. 10 2001 25 33
11. J. Classen, F. Paulsen, T. Hehr Effect of gemcitabine on acute and late radiation toxicity of skin and underlying soft tissues to single-dose irradiation in a nude mice model Int J Radiat Oncol Biol Phys 53 2002 197 205
12. V. Gregoire, S. Svilic, M. Beauduin Effect of gemcitabine on the tolerance of the lung to single-dose irradiation in CH3 mice Radiat Res 151 1999 747 749
13. C.P. Li, Y. Chao, K.H. Chi Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer Gemcitabine vs. 5-fluorouracil, a randomized controlled study Int J Radiat Oncol Biol Phys 57 2003 98 104
14. A.W. Blackstock, S.A. Bernard, F. Richards Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer J Clin Oncol 17 1999 2208 2212
15. J.W.G. van Putten, A. Price, A.H.D. van der Leest A phase I study of gemcitabine with concurrent radiotherapy in stage III locally advanced non-small cell lung cancer Clin Cancer Res 9 2003 2472 2477
16. P. Pattaranutaporn, C. Thirapakawong, Y. Chansilpa Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma Gynecol Oncol 81 2001 404 407
17. A. Eisbruch, D.S. Shewach, C.R. Bradford Radiation concurrent with gemcitabine for locally advanced head and neck cancer A phase I trial and intracellular drug incorporation study J Clin Oncol 19 2001 792 799
18. L. Bohm, W.P. Roos, A.M. Serafin Inhibition of DNA repair by pentoxifylline and related methylxanthine derivatives Toxicology 193 2003 153 160
19. H. Ely Is pentoxifylline the drug of the decade? J Am Acad Dermatol 30 1994 603 621
20. D.J. Honess, I.F. Dennis, N.M. Bleehen Pentoxifylline Its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice Radiother Oncol 28 1993 208 218
21. D.R. Collingridge, S. Rockwell Pentoxifylline improves the oxygenation and radiation response of BA1112 rat rhabdomyosarcomas and EMT6 mouse mammary carcinomas Int J Cancer 90 2000 256 264
22. F. Zywietz, L. Bohm, C. Sagowski, W. Kehrl Pentoxifylline enhances tumour oxygenation and radiosensitivity in a rhabdomyosarcoma during continuous hyperfractionated irradiation Strahlenther Onkol 180 2004 306 314
23. P. Zabel, M.M. Schonharting, D.T. Wolter Oxpentifylline in endotoxaemia Lancet 23 1989 1474 1477
24. 2 delay Cancer Res 55 1995 1643 1648
25. 2/M phase block enhances the cytotoxicity of daunorubicin, melphalan and cisplatin to p53 mutant human tumour cells Radiat Res 154 2000 640 649
26. K.J. Russel, L.W. Wiens, G.W. Demers Preferential radiosensitization of G1 checkpoint deficient cells by methylxanthanines Int J Radiat Oncol Biol Phys 36 1996 1099 1106
27. N.A. Asaad, Z. Zeng, J. Guan Homologous recombination is a potential target for caffeine radiosensitization in mammalian cells reduced caffeine radiosensitization in XRSS2 and XRSS3 mutants Oncogene 129 2000 5788 5800
28. 2 block abrogation, DNA double strand break repair and apoptosis in the radiosensitization of melanoma and squamous cell carcinoma cell lines Int J Radiat Biol 76 2000 1197 1208
29. L.Y. Yang, H. Jiang, K.M. Rangel RNA-polymerase II stalled on a DNA template during transcription elongation is ubiquitinated and the ubiquitination facilitates displacement of the elongation complex Int J Oncol 22 2003 683 689
30. M. Verheij, H. Bartelink Radiation-induced apoptosis Cell Tissue Res 301 2000 133 142
31. J.M. Brown, L.D. Attardi The role of apoptosis in cancer development and treatment response Nat Rev Cancer 3 2005 231 237
32. C. Belka, V. Jendrossek, M. Pruschy Apoptosis modulating drugs in combination with radiotherapy - current status and outlook Int J Radiat Oncol Biol Phys 58 2004 542 544
33. A.H. van der Luit, M. Budde, P. Ruurs Alkyl-lysophospholipids induce apoptosis via raft-mediated endocytosis and inhibition of phosphatidylcholine synthesis J Biol Chem 277 2002 39541 39547
34. M. Verheij, R. Bose, X.H. Lin Requirement for ceramide-initiated SAPK/JNK signaling in stress-induced apoptosis Nature 380 1996 75 79
35. G.A. Ruiter, S.F. Zerp, H. Bartelink Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis Cancer Res 59 1999 2457 2463
36. G.A. Ruiter, S.F. Zerp, H. Bartelink Anticancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway Anticancer Drugs 14 2003 167 173
37. S.R. Vink, J.H.M. Schellens, J. Engel The oral alkyl-phosphocholine perifosine potentiates the antitumor effect of radiation in vitro and in vivo Radiother Oncol 73 Suppl. 1 2004 S426
38. G.A. Ruiter, M. Verheij, S.F. Zerp Alkyl-lysophospholipids as anti-cancer agents and enhancers of radiation-induced apoptosis Int J Radiat Oncol Biol Phys 49 2001 415 419
39. M. Verheij, S.R. Vink, J.H.M. Schellens Phase I study of combined treatment with the oral alkyl-lysophospholipid (APL) perifosine and radiation in patients with advanced solid tumors Proc Am Soc Clin Oncol 23 2004 3064
40. J. Mendelsohn, Z. Fan Epidermal growth factor receptor family and chemosensitization J Natl Cancer Inst 89 1997 341 343
41. S.B. Noonberg, C.C. Benz Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily Role as anticancer agents Drugs 59 2000 753 767
42. L. Milas Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse Semin Radiat Oncol 11 2001 290 299
43. Y. Yarden, M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137
44. J. Grandis, M. Melhem, W. Gooding Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival J Natl Cancer Inst 90 1998 824 832
45. K.K. Ang, B.A. Berkey, X. Tu Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Res 62 2002 7350 7356
46. L. Milas, K. Mason, N. Hunter In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody Clin Cancer Res 6 2000 701 708
47. D. Raben, C. Bianco, L. Milas Targeted therapies and radiation for the treatment of head and neck cancer Are we making progress? Semin Radiat Oncol 14 2004 139 152
48. J.A. Bonner, J. Giralt, P.M. Harari Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck A phase III study of high dose radiation therapy with or without cetuximab Proc Am Soc Clin Oncol 23 2004 488
49. Z. Liao, L. Milas COX-2 and its inhibition as a molecular target in the prevention and treatment of lung cancer Expert Rev Anticancer Ther 4 2004 543 560
50. H. Choy, L. Milas Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors A rational advance? J Natl Cancer Inst 95 2003 1440 1452
51. N.K. Altorki, R.S. Keresztes, J.L. Port Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer J Clin Oncol 21 2003 2645 2650
52. Z. Liao, R. Komaki, L. Milas A phase I clinical trial of thoracic radiation and concurrent celecoxib for patients unfavourable performance status inoperable/unresectable non-small cell lung cancer Clin Cancer Res 11 2005 3342 3348
53. J. Folkman Role of angiogenesis in tumor growth and metastasis Semin Oncol 29 Suppl. 16 2002 15 18
54. P. Vaupel, F. Kallinowski, P. Okunieff Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors A review Cancer Res 49 1989 6449 6465
55. A.L. Harris Hypoxia - a key regulatory factor in tumour growth Nat Rev Cancer 2 2002 38 47
56. M.R. Horsman, J. Overgaard The oxygen effect and the tumour microenvironment G.G. Steel Basic clinical radiobiology 3rd ed 2002 Edward Arnold London 158 168
57. M.R. Horsman, J. Overgaard Overcoming tumour radioresistance resulting from hypoxia G.G. Steel Basic clinical radiobiology 3rd ed 2002 Edward Arnold London 169 181
58. J. Overgaard Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors Oncol Res 6 1994 509 518
59. Y. Shimaboto, T. Kubota, K. Kishii Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole Radiother Oncol 56 2000 265 270
60. M.R. Horsman Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours Acta Oncol 34 1995 571 587
61. J.H.A.M. Kaanders, J. Bussink, A.J. van der Kogel ARCON A novel biology-based approach in radiotherapy Lancet Oncol 3 2002 728 737
62. C. Grau, J.P. Agarwal, K. Jabeen Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer Results of the IAEA multicentre randomised trial Radiother Oncol 67 2003 17 26
63. J.M. Brown, W.R. Wilson Exploiting tumor hypoxia in cancer treatment Nat Rev Cancer 4 2004 437 447
64. D. Rischin, L. Peters, R. Fisher Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer A randomized phase II trial of the Trans-Tasman Radiation Oncology group (TROG 98.02) J Clin Oncol 23 2005 79 87
65. L.H. Patterson, S.R. McKeown, K. Ruparelia Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent Br J Cancer 82 2000 1984 1990
66. D.W. Siemann, K.H. Warrington, M.R. Horsman Vascular targeting agents Adjuvants to radiation therapy Radiother Oncol 57 2000 5 12
67. P. Wachsberger, R. Burd, A.P. Dicker Tumor response to ionizing radiation combined with angiogenesis or vascular targeting agents Exploiting mechanisms of interaction Clin Cancer Res 9 2003 1957 1971
68. R. Murata, Y. Nishimura, M. Hiraoka An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma Int J Radiat Oncol Biol Phys 37 1997 1107 1113
69. H. Gong, C. Pottgen, G. Stuben Arginine deiminase and other antiangiogenic agents inhibit unfavourable neuroblastoma growth Potentiation by irradiation Int J Cancer 106 2003 723 728
70. M.R. Horsman, R. Murata Combination of vascular targeting agents with thermal and radiation therapy Int J Radiat Oncol Biol Phys 54 2002 1518 1523
71. D.W. Siemann, D.J. Chaplin, M.R. Horsman Vascular targeting therapies for treatment of malignant disease Cancer 100 2004 2491 2499
72. R.J. Klasa, A.M. Gillum, R.E. Klem Oblimersen Bcl-2 antisense Facilitating apoptosis in anticancer treatment Antisense Nucleic Acid Drug Dev 12 2002 193 213
73. B. Jansen, U. Zangmeister Antisense therapy for cancer - The time of truth Lancet Oncol 3 2002 672 683
74. N. Kyprianou, E.D. King, D. Bradbury Bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells Int J Cancer 70 1997 341 348
75. C. Breton, M.D. Story, R.E. Meyn Bcl-2 expression correlates with apoptosis induction but not loss of clonogenic survival in small cell lung cancer cell lines treated with etoposide Anticancer Drugs 9 1998 751 757
76. K.D. Held Radiation-induced apoptosis and its relationship to loss of clonogenic survival Apoptosis 2 1997 265 282
77. V. Wacheck, E. Selzer, P. Gunsberg Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer cells Br J Cancer 89 2003 1352 1357
78. H. Skvara, C. Thallinger, V. Wacheck Mcl-1 blocks radiation-induced apoptosis and clonogenic cell death Anticancer Res 25 2005 2697 2703
79. C. Thallinger, M.F. Wolschek, H. Maierhofer Mcl-1 is a novel therapeutic target for human sarcoma Synergistic inhibition of human sarcoma xerotransplants by a combination of mcl-1 antisense oligonucleotides with low dose cyclophosphamide Clin Cancer Res 10 2004 4185 4191
80. B. Jansen, V. Wacheck, E. Heere-Ress Chemosensitization of malignant melanoma by bcl2 antisense therapy Lancet 356 2000 1728 1733
81. B. Jansen, H. Schlagbayer-Wadl, B.D. Brown Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice Nat Med 1998 4232 4234
82. W.F. Anderson Human gene therapy Nature 392 1998 25 30
83. D.L. Shawler, H. Fakhrai, C. Van Beveren Gene therapy approaches to enhance antitumor immunity Adv Pharmacol 40 1997 309 337
84. K. Lumniczky, S.Z. Désaknai, L. Mangel Local tumor irradiation augments the anti-tumor effect of cytokine producing autologous cancer cell vaccines in a murine glioma model Cancer Gene Ther 9 2002 44 52
85. S.Z. Desaknai, K. Lumniczky, O. Esik Local tumor irradiation enhances the anti-tumor effect of a double-suicide gene therapy system in a murine glioma model J Gene Med 5 2003 377 385
86. V. Gregoire, J.F. Rosier, M. De Bast Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro Radiother Oncol 63 2002 329 338
87. R.R. Weichselbaum, D.E. Hallahan, Z. Fuks Radiation induction of immediate early genes Effectors of the radiation stress response Int J Radiat Oncol Biol Phys 30 1994 229 234
88. R.R. Weichselbaum, D.E. Hallahan, M.A. Beckett Gene therapy targeted by radiation preferentially radiosensitizes tumor cells Cancer Res 54 1994 4266 4269
89. G.U. Dachs, G.J. Dougherty, I.J. Stratford Targeting gene therapy to cancer A review Oncol Res 9 1997 313 325
90. D.E. Hallahan, H.J. Mauceri, L.P. Seung Spatial and temporal control of gene therapy using ionizing radiation Nat Med 1 1995 786 791
91. T. Joki, M. Nakamura, T. Ohno Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to gancyclovir Hum Gene Ther 6 1995 1507 1513
92. T. Takahashi, Y. Namiki, T. Ohno Induction of the suicide HSV TK gene by activation of the EGR 1 promoter with radioisotopes Hum Gene Ther 8 1997 827 833
93. R. Datta, E. Rubin, V. Sukhatme Ionizing radiation activates transcription of the EGR1 gene via CArG elements Proc Natl Acad Sci USA 89 1992 10149 10153
94. 6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation Proc Natl Acad Sci USA 90 1993 2419 2422
95. Y. Manome, T. Kunieda, P.Y. Wen Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the EGR-1 promoter Activation by ionizing radiation or uptake of radioactive iodo-deoxyuridine Hum Gene Ther 9 1998 1409 1417
96. R.R. Weichselbaum, D.W. Kufe, S. Hellman Radiation-induced tumour necrosis factor-α expression Clinical application of transcriptional and physical targeting of gene therapy Lancet Oncol 3 2002 665 671
97. B. Marples, S.D. Scott, J.H. Hendry Development of synthetic promoters for radiation-mediated gene therapy Gene Ther 7 2000 511 517
98. S.D. Scott, B. Marples, J.H. Hendry A radiation-controlled molecular switch for use in gene therapy of cancer Gene Ther 7 2000 1121 1125
99. I.R. Hart Tissue specific promoters in targeting systemically delivered gene therapy Semin Oncol 23 1996 154 158
100. S.J. Collis, A. Tighe, S.D. Scott Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells Nucleic Acids Res 29 2001 1534 1538
101. T. Robson, D.G. Hirst Transcriptional targeting in cancer gene therapy J Biomed Biotechnol 2003 2003 110 137
102. A.V. Patterson, K.J. Williams, R.L. Cowen Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours Gene Ther 9 2002 946 954